|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.32 USD | -1.71% |
|
-2.64% | -30.03% |
| 06-02 | Daxor Says Received US Patent for Remote Blood Volume Monitor Technology | MT |
| 04-26 | 5,061,267 Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 27-APR-2026. | CI |
Projected Income Statement: Daxor Corporation
| Fiscal Period: December | 2021 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| Net sales 1 | 0.2781 | 0.1197 | 0.0267 | 11.9 | 20.8 |
| Change | - | - | -77.7% | 44,485.99% | 74.79% |
| EBITDA | - | - | - | - | - |
| Change | - | - | - | - | - |
| EBIT 1 | - | - | -1.107 | -1.2 | -0.2 |
| Change | - | - | - | -8.4% | 83.33% |
| Interest Paid | -0.0196 | - | - | - | - |
| Earnings before Tax (EBT) 1 | 4.748 | - | 9.17 | -1.2 | -0.2 |
| Change | - | - | - | -113.09% | 83.33% |
| Net income 1 | 4.748 | 0.5363 | 9.17 | -1.2 | -0.2 |
| Change | - | - | 1,609.73% | -113.09% | 83.33% |
| Announcement Date | 2/28/22 | 3/3/25 | 3/2/26 | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: Daxor Corporation
| Fiscal Period: December | 2021 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Change | - | - | - | - | - |
| Announcement Date | 2/28/22 | 3/3/25 | 3/2/26 | - | - |
Estimates
Cash Flow Forecast: Daxor Corporation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| CAPEX 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Free Cash Flow (FCF) 1 | -0.5015 | 0.3782 | 0.9025 | 0.1611 | 0.309 | 0.1002 |
| Change | - | 175.42% | 138.62% | -82.15% | 91.77% | -67.55% |
| Announcement Date | 2/25/21 | 2/28/22 | 3/1/23 | 3/15/24 | 3/3/25 | 3/2/26 |
1USD in Million
Estimates
Forecast Financial Ratios: Daxor Corporation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | - | - | - | - | - |
| EBIT Margin (%) | - | - | - | - | - | -4,147.58% | -10.08% | -0.96% |
| EBT Margin (%) | - | 1,707.43% | - | - | - | 34,356.58% | -10.08% | -0.96% |
| Net margin (%) | - | 1,707.43% | - | - | 448.02% | 34,356.58% | -10.08% | -0.96% |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | -1.37% | -2.24% | -1.95% | -1.51% | -2.51% | -1.64% | - | - |
| ROE | -11.99% | 25.79% | 20.66% | 0.89% | 1.54% | 22.45% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | -1.59x | 9.88x | 1.36x | 4.69x | 2.36x | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| EPS 1 | - | - | - | - | - | 1.839 | -0.21 | -0.03 |
| Change | - | - | - | - | - | - | -111.42% | 85.71% |
| Nbr of stocks (in thousands) | - | - | - | - | - | 4,984 | 5,827 | 5,827 |
| Announcement Date | - | - | - | - | - | 3/2/26 | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -49.1x | -344x |
| PBR | - | - |
| EV / Sales | 5.05x | 2.89x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.32USD
Average target price
22.50USD
Spread / Average Target
+118.02%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
- Financials Daxor Corporation
Select your edition
All financial news and data tailored to specific country editions
